Drugs / SIF001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07051629 | Jun 2025 → Jan 2027 expected | epilepsy | Suninflam Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIF001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07051629 ↗ |
| Modality | Monoclonal antibody | “SIF001, a monoclonal antibody” NCT07051629 ↗ |
| Route | Intravenous | “SIF001 infused intravenously over one hour” NCT07051629 ↗ |